NPHCDA says no change in plan to vaccinate four million Nigerians

636

The National Primary Health Car Development Agency,NPHCDA has restated it’s commitment to continue with the programme to vaccinate four million Nigerians beginning with front line workers under the on going Coronavirus vaccination programme.
This pledge was contained in a statement by Mohammed Ohitoto,head public relations unit of the agency.
Details below:
National Primary Health Care Development Agency

PRESS STATEMENT:

Nigeria is continuing in the process of administering roughly 4 million doses of the Oxford/AstraZeneca vaccine, beginning with our frontline health workers and vulnerable individuals. There has been no change to current plans or supply.

A huge number of countries around the world are administering the Oxford/AstraZeneca vaccine, including much of Europe, and United Kingdom which have administered the most doses of AstraZeneca globally. The World Health Organization, British and European health regulators all continue to advocate for the use of AstraZeneca.

AstraZeneca’s strong effectiveness against COVID-19 has been demonstrated in clinical and human trials: it has been shown to be 76% effective at preventing COVID-19 and 100% effective at preventing severe disease and hospitalization.

Nigeria’s health authorities followed closely recent pronouncements from Europe’s regulator, the EMA. The head of the EMA stated that, according to scientific knowledge, there is no evidence to support restricting the use of the vaccine in any population.

The NPHCDA’s priority is the health and safety of the Nigerian people, and our decisions and advice are guided by best practice and scientific evidence. We are confident in AstraZeneca’s ability to save lives.

Vaccines save lives!

Signed:
Mohammad Ohitoto
Head, Public Relations Unit

Kindly support the growth of journalism in Nigeria
To Receive FREE Newdawn News Online on your phone, text your number to +2348104502834


Reactions to stories published can be sent to us at info@newdawnngr.com


Leave a Reply

Your email address will not be published. Required fields are marked *